Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Kyoto University
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04413344CT.gov Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Familial Alzheimer Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 2-Bromo-?-ergocryptine (this asset) | Kyoto University | P1/2 | CCC · 52 |
| Lecanemab | Washington University School of Medicine | P3 | BB |
| Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, Dimer | Washington University School of Medicine | P2/3 | B |
| Remternetug | Washington University School of Medicine | P2/3 | B |
| Solanezumab | Washington University School of Medicine | P2/3 | CCC |
| Immunoglobulin G1, Anti-(Human 1-40-.Beta.-Amyloid/Human 1-42-.Beta.-Amyloid) (Human Monoclonal .Gamma.1-Chain), Disulfide With Human Monoclonal .Kappa.-Chain, Dimer | Washington University School of Medicine | P2/3 | CC |
Other indications for 2-Bromo-?-ergocryptine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Parkinson Disease | — | P4 | BB · 69 |
| Prediabetes Syndrome | — | P4 | BB · 65 |
| Eating Disorder | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- LecanemabWashington University School of MedicineBB
- Immunoglobulin G1 [De-449-Lysine], Anti-(Human Tau Protein) (Human-Mus Musculus Monoclonal E2814 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal E2814 .Kappa.-Chain, DimerWashington University School of MedicineB
- RemternetugWashington University School of MedicineB
- SolanezumabWashington University School of MedicineCCC
- Immunoglobulin G1, Anti-(Human 1-40-.Beta.-Amyloid/Human 1-42-.Beta.-Amyloid) (Human Monoclonal .Gamma.1-Chain), Disulfide With Human Monoclonal .Kappa.-Chain, DimerWashington University School of MedicineCC
Citation
Floatz Terminal. 2-Bromo-?-ergocryptine in Familial Alzheimer Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/2-bromo-ergocryptine-familial-alzheimer-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →